Details of the Drug Combination

General Information of Drug Combination (ID: DCTDIUD)

Drug Combination Name
Gefitinib Azacitidine
Indication
Disease Entry Status REF
Ovarian serous cystadenocarcinoma Investigative [1]
Component Drugs Gefitinib   DM15F0X Azacitidine   DMTA5OE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-OV-3
Zero Interaction Potency (ZIP) Score: 2.15
Bliss Independence Score: 3.31
Loewe Additivity Score: 0.93
LHighest Single Agent (HSA) Score: 2.72

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gefitinib
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [2]
Glioblastoma 2A00 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Head and neck cancer 2D42 Phase 3 [3]
Urethral cancer 2C93 Phase 2 [3]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Gefitinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Gefitinib Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Gefitinib Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [15]
------------------------------------------------------------------------------------
Gefitinib Interacts with 103 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases ADR [17]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [18]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Increases Expression [19]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Decreases Expression [19]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [19]
Fibroblast growth factor 6 (FGF6) OTRJ679P FGF6_HUMAN Increases Expression [19]
Ski oncogene (SKI) OT4KJ8F6 SKI_HUMAN Increases Expression [19]
Erythropoietin receptor (EPOR) OTUIOEU3 EPOR_HUMAN Increases Expression [19]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [19]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [19]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [19]
Cytochrome P450 2F1 (CYP2F1) OTY3HJH1 CP2F1_HUMAN Decreases Expression [19]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Increases Expression [19]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Decreases Expression [19]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [19]
DNA mismatch repair protein Mlh1 (MLH1) OTG5XDD8 MLH1_HUMAN Decreases Expression [19]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [19]
Epidermal growth factor receptor substrate 15 (EPS15) OT7NPP8U EPS15_HUMAN Increases Expression [19]
Neuronal pentraxin-2 (NPTX2) OT3SSJDP NPTX2_HUMAN Decreases Expression [19]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Decreases Expression [19]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Decreases Expression [19]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2) OT3JPRCQ GBB2_HUMAN Decreases Expression [19]
Retinal guanylyl cyclase 1 (GUCY2D) OT81UJI0 GUC2D_HUMAN Decreases Expression [19]
Cell growth regulator with RING finger domain protein 1 (CGRRF1) OTLMNRCL CGRF1_HUMAN Increases Expression [19]
Dual specificity protein phosphatase 9 (DUSP9) OTZZWEQL DUS9_HUMAN Decreases Expression [19]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [20]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [21]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Expression [21]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [21]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [22]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [23]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) OTVT4YA1 ATG7_HUMAN Increases Expression [24]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [25]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [7]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [26]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Affects Expression [27]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Phosphorylation [28]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Phosphorylation [29]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) OTZE5Q7R DOA_HUMAN Affects Expression [27]
Heat shock protein HSP 90-alpha (HSP90AA1) OTLG1WPK HS90A_HUMAN Increases Secretion [26]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Phosphorylation [30]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Secretion [26]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [31]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Secretion [26]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Secretion [32]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [7]
Platelet endothelial cell adhesion molecule (PECAM1) OTXOM4D9 PECA1_HUMAN Decreases Expression [7]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [24]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [33]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [18]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Secretion [26]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Expression [34]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Expression [34]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Activity [26]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [18]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Affects Expression [27]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [35]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [23]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [24]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Increases Expression [25]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [7]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [18]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [36]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [31]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [22]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Expression [34]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [37]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [38]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [36]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [39]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Expression [40]
MHC class I polypeptide-related sequence A (MICA) OTPEIEAR MICA_HUMAN Increases Expression [40]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Expression [41]
Serine protease HTRA1 (HTRA1) OTR8ACBF HTRA1_HUMAN Increases Expression [42]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [27]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [24]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [43]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Decreases Response To Substance [44]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [45]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Affects Response To Substance [46]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Decreases Response To Substance [47]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Response To Substance [48]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Affects Response To Substance [49]
RNA-binding protein 7 (RBM7) OTFIWTMF RBM7_HUMAN Affects Response To Substance [49]
Cell death regulator Aven (AVEN) OTGIN5YK AVEN_HUMAN Affects Response To Substance [49]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Response To Substance [50]
Phospholipase B-like 1 (PLBD1) OTHYEB4W PLBL1_HUMAN Affects Response To Substance [49]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Response To Substance [51]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Response To Substance [31]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Decreases Response To Substance [49]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Affects Response To Substance [49]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Response To Substance [51]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Affects Response To Substance [10]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [52]
Ceramide transfer protein (CERT1) OTNUCNHX CERT_HUMAN Affects Response To Substance [49]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Affects Response To Substance [53]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Affects Response To Substance [49]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [54]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Affects Response To Substance [49]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Response To Substance [51]
Pericentrin (PCNT) OTW4Z65J PCNT_HUMAN Decreases Response To Substance [47]
Coronin-1C (CORO1C) OTXDF9T3 COR1C_HUMAN Affects Response To Substance [49]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 103 DOT(s)
Indication(s) of Azacitidine
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Chronic myelomonocytic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Myelodysplastic syndrome 2A37 Approved [5]
Myeloproliferative neoplasm 2A20 Approved [4]
Plasma cell myeloma 2A83.1 Approved [4]
Azacitidine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA [cytosine-5]-methyltransferase (DNMT) TTHVCUP NOUNIPROTAC Inhibitor [59]
------------------------------------------------------------------------------------
Azacitidine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [60]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [61]
------------------------------------------------------------------------------------
Azacitidine Interacts with 275 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Affects Expression [62]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [63]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [63]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Expression [63]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [63]
Sulfotransferase 1C2 (SULT1C2) OT07MMZS ST1C2_HUMAN Increases Expression [55]
Phospholipid phosphatase 1 (PLPP1) OT0IIMI5 PLPP1_HUMAN Increases Expression [55]
Tectonin beta-propeller repeat-containing protein 2 (TECPR2) OT1UFECZ TCPR2_HUMAN Increases Expression [55]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Decreases Expression [55]
Multiple epidermal growth factor-like domains protein 6 (MEGF6) OTEUYTP1 MEGF6_HUMAN Decreases Expression [55]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Decreases Expression [55]
Integrin beta-2 (ITGB2) OTEKPEPR ITB2_HUMAN Decreases Expression [55]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [55]
Receptor-type tyrosine-protein phosphatase C (PTPRC) OT6KOR77 PTPRC_HUMAN Increases Expression [55]
Delta-aminolevulinic acid dehydratase (ALAD) OTHM9GSH HEM2_HUMAN Decreases Expression [55]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Increases Expression [55]
Heat shock 70 kDa protein 6 (HSPA6) OTH4S7WB HSP76_HUMAN Increases Expression [55]
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) OT4L2SSB GBRB1_HUMAN Increases Expression [55]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [55]
Pro-thyrotropin-releasing hormone (TRH) OT02UY2V TRH_HUMAN Decreases Expression [55]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Increases Expression [55]
Protein PML (PML) OT6SM2GD PML_HUMAN Increases Expression [55]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Increases Expression [55]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Decreases Methylation [55]
LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1) OT729S0T LIMS1_HUMAN Increases Expression [55]
E3 SUMO-protein ligase RanBP2 (RANBP2) OTFG5CVF RBP2_HUMAN Increases Expression [55]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Increases Expression [55]
Ras-related protein Rab-13 (RAB13) OTIQ484I RAB13_HUMAN Decreases Methylation [55]
Lysozyme C (LYZ) OTD7H0G6 LYSC_HUMAN Increases Expression [55]
Claudin-10 (CLDN10) OT2CVAKY CLD10_HUMAN Decreases Expression [55]
Sushi repeat-containing protein SRPX (SRPX) OT5B9LXS SRPX_HUMAN Decreases Expression [55]
Protein delta homolog 1 (DLK1) OTE1VLNB DLK1_HUMAN Decreases Methylation [55]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [55]
Collagen alpha-1(XIV) chain (COL14A1) OTLNJ13O COEA1_HUMAN Increases Expression [55]
Equilibrative nucleoside transporter 2 (SLC29A2) OTUAOB8T S29A2_HUMAN Decreases Expression [55]
Cytohesin-1 (CYTH1) OTYH9NRJ CYH1_HUMAN Increases Expression [55]
C3a anaphylatoxin chemotactic receptor (C3AR1) OT8J0TF8 C3AR_HUMAN Increases Expression [55]
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F) OT750IJM ABC3F_HUMAN Increases Expression [55]
Angiogenic factor with G patch and FHA domains 1 (AGGF1) OTA7U2T8 AGGF1_HUMAN Increases Expression [55]
E3 ubiquitin-protein ligase Praja-1 (PJA1) OTFKTMEI PJA1_HUMAN Increases Expression [55]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [55]
Tetraspanin-32 (TSPAN32) OTSXW7EW TSN32_HUMAN Decreases Expression [55]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Decreases Expression [55]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Decreases Expression [55]
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1A) OTVTB5R5 PI51A_HUMAN Decreases Expression [55]
Centromere protein O (CENPO) OTXAH83Y CENPO_HUMAN Increases Expression [55]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1) OTU230MC ISCA1_HUMAN Increases Expression [55]
E3 ubiquitin-protein ligase TRIM8 (TRIM8) OTS6JFR0 TRIM8_HUMAN Increases Expression [55]
Uncharacterized protein C6orf62 (C6ORF62) OTGK4G35 CF062_HUMAN Increases Expression [55]
Metal transporter CNNM2 (CNNM2) OTZHO8WU CNNM2_HUMAN Decreases Expression [55]
Pantothenate kinase 3 (PANK3) OT77CFJ6 PANK3_HUMAN Decreases Expression [55]
DNA dC->dU-editing enzyme APOBEC-3G (APOBEC3G) OT410VP5 ABC3G_HUMAN Increases Expression [55]
Neuritin (NRN1) OTWJG0SO NRN1_HUMAN Decreases Expression [55]
NTF2-related export protein 2 (NXT2) OTK82YVT NXT2_HUMAN Increases Expression [55]
THUMP domain-containing protein 1 (THUMPD1) OTKU8KWH THUM1_HUMAN Increases Expression [55]
Protein FAM8A1 (FAM8A1) OT1QVTGS FA8A1_HUMAN Increases Expression [55]
Type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6) OTB17Q43 SIA10_HUMAN Increases Expression [55]
Methionine-R-sulfoxide reductase B2, mitochondrial (MSRB2) OTURGRA8 MSRB2_HUMAN Increases Expression [55]
Mitotic spindle assembly checkpoint protein MAD1 (MAD1L1) OTJCX8K9 MD1L1_HUMAN Decreases Expression [55]
Signal-regulatory protein beta-1 (SIRPB1) OTGHALWJ SIRB1_HUMAN Decreases Expression [56]
Syntenin-1 (SDCBP) OTS3NCC5 SDCB1_HUMAN Decreases Expression [56]
Complexin-1 (CPLX1) OT7UIGTP CPLX1_HUMAN Increases Expression [56]
Nephrocystin-1 (NPHP1) OTZHCFFQ NPHP1_HUMAN Increases Expression [56]
Phosphatase and actin regulator 2 (PHACTR2) OTWMX2A8 PHAR2_HUMAN Increases Expression [56]
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1) OT4TMERS NFAC1_HUMAN Increases Expression [56]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Decreases Expression [56]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases Expression [56]
Cystatin-C (CST3) OTNZ6AO4 CYTC_HUMAN Increases Expression [56]
Cystatin-S (CST4) OTXXM8EH CYTS_HUMAN Increases Expression [56]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [56]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Decreases Expression [56]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Increases Expression [56]
Neurofilament light polypeptide (NEFL) OTQESJV4 NFL_HUMAN Increases Expression [56]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Increases Expression [56]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Expression [56]
Profilin-1 (PFN1) OTHTGA1H PROF1_HUMAN Increases Expression [56]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Expression [56]
Tropomyosin beta chain (TPM2) OTA1L0P8 TPM2_HUMAN Increases Expression [56]
Transcription factor Sp1 (SP1) OTISPT4X SP1_HUMAN Decreases Expression [56]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [56]
Insulin-like growth factor-binding protein 1 (IGFBP1) OT6UQV2K IBP1_HUMAN Increases Expression [56]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Decreases Expression [56]
Glycodelin (PAEP) OTQA0NV4 PAEP_HUMAN Decreases Expression [56]
E3 SUMO-protein ligase EGR2 (EGR2) OTAVQ78J EGR2_HUMAN Increases Expression [56]
Pregnancy-specific beta-1-glycoprotein 1 (PSG1) OT1U4ZZW PSG1_HUMAN Increases Expression [56]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Decreases Expression [56]
Parathyroid hormone-related protein (PTHLH) OTI1JF13 PTHR_HUMAN Decreases Expression [56]
Plastin-3 (PLS3) OTYBM4PK PLST_HUMAN Decreases Expression [56]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [56]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Increases Expression [56]
Carboxypeptidase E (CPE) OTXNTV79 CBPE_HUMAN Increases Expression [56]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Increases Expression [56]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Decreases Expression [56]
Desmin (DES) OTI09KBW DESM_HUMAN Increases Expression [56]
Plasma membrane calcium-transporting ATPase 1 (ATP2B1) OT5MXG9W AT2B1_HUMAN Decreases Expression [56]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [56]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Increases Expression [56]
Fibroblast growth factor 7 (FGF7) OTGK6ANL FGF7_HUMAN Decreases Expression [56]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [56]
Transcription elongation factor A protein 1 (TCEA1) OTBFO594 TCEA1_HUMAN Decreases Expression [56]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases Expression [56]
Tenascin (TNC) OTK4FSHR TENA_HUMAN Decreases Expression [56]
V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C) OTKPL09B VATL_HUMAN Increases Expression [56]
Protein ITPRID2 (ITPRID2) OTO3JDX5 ITPI2_HUMAN Increases Expression [56]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [56]
Interleukin-12 subunit beta (IL12B) OT0JF8A3 IL12B_HUMAN Increases Expression [56]
Neurotensin/neuromedin N (NTS) OTPGDNQS NEUT_HUMAN Decreases Expression [56]
Guanylate-binding protein 2 (GBP2) OTVU4G07 GBP2_HUMAN Decreases Expression [56]
MHC class II transactivator (CIITA) OTRJNZFO C2TA_HUMAN Increases Expression [56]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [56]
Exosome RNA helicase MTR4 (MTREX) OTSQY30V MTREX_HUMAN Increases Expression [56]
Alpha-S1-casein (CSN1S1) OTXOW6XJ CASA1_HUMAN Increases Expression [56]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Decreases Expression [56]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Increases Expression [56]
Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) OT6E2OW6 ENTP1_HUMAN Increases Expression [56]
Ephrin-A3 (EFNA3) OTJGOUMZ EFNA3_HUMAN Increases Expression [56]
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases Expression [56]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [56]
Microfibrillar-associated protein 2 (MFAP2) OTMHVBTV MFAP2_HUMAN Decreases Expression [56]
Laminin subunit beta-2 (LAMB2) OT71OI2Y LAMB2_HUMAN Increases Expression [56]
NHP2-like protein 1 (SNU13) OTH56TIH NH2L1_HUMAN Increases Expression [56]
Homeobox protein DLX-6 (DLX6) OT0FIJHY DLX6_HUMAN Increases Expression [56]
Neurotrypsin (PRSS12) OT1MYL3L NETR_HUMAN Decreases Expression [56]
Elongation factor 1-alpha 1 (EEF1A1) OT00THXS EF1A1_HUMAN Decreases Expression [56]
Microtubule-associated protein 1A (MAP1A) OTHO8K43 MAP1A_HUMAN Decreases Expression [56]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [56]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2) OTQR5SXD CX6A2_HUMAN Increases Expression [56]
cAMP-responsive element modulator (CREM) OTJIJ5AL CREM_HUMAN Decreases Expression [56]
Caldesmon (CALD1) OTNJKJ6Q CALD1_HUMAN Increases Expression [56]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [56]
Serine/threonine-protein kinase PAK 1 (PAK1) OT17LZNZ PAK1_HUMAN Increases Expression [56]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5) OT6T408U MP2K5_HUMAN Decreases Expression [56]
Chitotriosidase-1 (CHIT1) OTPQR0A6 CHIT1_HUMAN Increases Expression [56]
Ras and Rab interactor 1 (RIN1) OTPBROUD RIN1_HUMAN Increases Expression [56]
Keratin, type I cuticular Ha2 (KRT32) OTZCGZYT K1H2_HUMAN Increases Expression [56]
Semaphorin-3A (SEMA3A) OTQJSV7W SEM3A_HUMAN Increases Expression [56]
Ras GTPase-activating protein 3 (RASA3) OT9C54MN RASA3_HUMAN Increases Expression [56]
Mediator of DNA damage checkpoint protein 1 (MDC1) OTEUQH4J MDC1_HUMAN Increases Expression [56]
Transmembrane glycoprotein NMB (GPNMB) OTB7KQKV GPNMB_HUMAN Decreases Expression [56]
Mortality factor 4-like protein 2 (MORF4L2) OT8OI3EC MO4L2_HUMAN Decreases Expression [56]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Increases Expression [56]
Serine/threonine-protein kinase 38 (STK38) OTKMYCYR STK38_HUMAN Decreases Expression [56]
Serine/threonine-protein phosphatase 2A activator (PTPA) OTRGFOI7 PTPA_HUMAN Increases Expression [56]
Reticulocalbin-1 (RCN1) OT3JBGAG RCN1_HUMAN Decreases Expression [56]
Olfactory receptor 8B8 (OR8B8) OTCISNYV OR8B8_HUMAN Increases Expression [56]
Leukotriene B4 receptor 1 (LTB4R) OT3SRH4H LT4R1_HUMAN Decreases Expression [56]
Serine/arginine-rich splicing factor 7 (SRSF7) OTRS4W4S SRSF7_HUMAN Decreases Expression [56]
Guanylate kinase (GUK1) OTLI0HRU KGUA_HUMAN Increases Expression [56]
Filamin A-interacting protein 1-like (FILIP1L) OTPY8IMS FIL1L_HUMAN Decreases Expression [56]
Nucleolar MIF4G domain-containing protein 1 (NOM1) OTWZSJJC NOM1_HUMAN Decreases Expression [56]
Opioid growth factor receptor-like protein 1 (OGFRL1) OT6QGBYE OGRL1_HUMAN Increases Expression [56]
Serine/threonine-protein kinase MRCK alpha (CDC42BPA) OTCPFOSA MRCKA_HUMAN Decreases Expression [56]
Extracellular sulfatase Sulf-1 (SULF1) OTJCNCO0 SULF1_HUMAN Decreases Expression [56]
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (GCNT2) OTRUIMC4 GNT2A_HUMAN Decreases Expression [56]
Oxidation resistance protein 1 (OXR1) OTPIDMT3 OXR1_HUMAN Increases Expression [56]
Alpha-2,8-sialyltransferase 8B (ST8SIA2) OTRBBBD8 SIA8B_HUMAN Decreases Expression [56]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Decreases Expression [56]
G-patch domain and KOW motifs-containing protein (GPKOW) OTGS3H0M GPKOW_HUMAN Increases Expression [56]
Rho guanine nucleotide exchange factor 2 (ARHGEF2) OTBQTFRT ARHG2_HUMAN Decreases Expression [56]
Homogentisate 1,2-dioxygenase (HGD) OTTKLQOO HGD_HUMAN Increases Expression [56]
Secretory carrier-associated membrane protein 4 (SCAMP4) OTSCZTJ5 SCAM4_HUMAN Increases Expression [56]
Protein bicaudal D homolog 1 (BICD1) OT78IYPF BICD1_HUMAN Decreases Expression [56]
Ankyrin repeat and SOCS box protein 2 (ASB2) OTF9LV7L ASB2_HUMAN Increases Expression [56]
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Decreases Expression [56]
Bcl-2-like protein 13 (BCL2L13) OT2VRFTM B2L13_HUMAN Increases Expression [56]
RNA helicase Mov10l1 (MOV10L1) OTP978LK M10L1_HUMAN Increases Expression [56]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Increases Expression [56]
Ras-related protein Rab-1B (RAB1B) OTAFCUAS RAB1B_HUMAN Increases Expression [56]
Semaphorin-6C (SEMA6C) OT1N59T5 SEM6C_HUMAN Increases Expression [56]
Sentrin-specific protease 3 (SENP3) OTFQDOMC SENP3_HUMAN Increases Expression [56]
Ribonuclease P protein subunit p21 (RPP21) OT53MDNE RPP21_HUMAN Increases Expression [56]
Protocadherin-18 (PCDH18) OTTLQWRN PCD18_HUMAN Decreases Expression [56]
Protein S100-A14 (S100A14) OTVFJJ91 S10AE_HUMAN Decreases Expression [56]
Tryptase gamma (TPSG1) OTDESHKT TRYG1_HUMAN Decreases Expression [56]
Rho GTPase-activating protein 35 (ARHGAP35) OTJ8POG0 RHG35_HUMAN Increases Expression [56]
Neuroligin-3 (NLGN3) OTKDEC1Q NLGN3_HUMAN Increases Expression [56]
Polycystin-2-like protein 1 (PKD2L1) OT1KJDAT PK2L1_HUMAN Increases Expression [56]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Decreases Expression [56]
Cytoplasmic phosphatidylinositol transfer protein 1 (PITPNC1) OT64TTGC PITC1_HUMAN Decreases Expression [56]
Transcription factor SOX-13 (SOX13) OTCIF6KC SOX13_HUMAN Decreases Expression [56]
Afadin- and alpha-actinin-binding protein (SSX2IP) OTEIZ7N1 ADIP_HUMAN Increases Expression [56]
Transmembrane emp24 domain-containing protein 3 (TMED3) OTNOPHHC TMED3_HUMAN Increases Expression [56]
Protocadherin beta-4 (PCDHB4) OTF665E0 PCDB4_HUMAN Decreases Expression [56]
Protocadherin beta-14 (PCDHB14) OTFZF1ST PCDBE_HUMAN Decreases Expression [56]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Increases Expression [56]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [64]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Increases Expression [64]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [64]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Increases Expression [64]
Hepatocyte nuclear factor 4-alpha (HNF4A) OTY1TOAB HNF4A_HUMAN Increases Expression [64]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Increases Expression [64]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Increases Expression [64]
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Affects Expression [62]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [65]
Aquaporin-9 (AQP9) OTLGH5ZY AQP9_HUMAN Increases Expression [66]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (GNG7) OTHS1L0E GBG7_HUMAN Affects Methylation [67]
Claudin-7 (CLDN7) OTNE0XHQ CLD7_HUMAN Decreases Expression [68]
Claudin-9 (CLDN9) OTCKI2IZ CLD9_HUMAN Increases Expression [69]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [65]
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Decreases Methylation [70]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [71]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [72]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [73]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Affects Methylation [74]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Affects Methylation [74]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [75]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Expression [76]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Increases Expression [77]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Increases Expression [78]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Increases Expression [76]
Histone H1.0 (H1-0) OTRLJK4Z H10_HUMAN Increases Expression [79]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Affects Expression [62]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Decreases Expression [80]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Expression [76]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [81]
Chromogranin-A (CHGA) OTXYX5JH CMGA_HUMAN Decreases Expression [80]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [76]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [82]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [80]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Decreases Methylation [83]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [84]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Expression [85]
Thyrotropin receptor (TSHR) OT0BC8LB TSHR_HUMAN Increases Expression [78]
Hepatocyte nuclear factor 1-alpha (HNF1A) OT9DOUKL HNF1A_HUMAN Increases Expression [66]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [75]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [86]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [76]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Expression [87]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Affects Methylation [88]
Oxytocin receptor (OXTR) OT7WFW4U OXYR_HUMAN Decreases Expression [75]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Affects Expression [62]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Methylation [89]
Melanoma-associated antigen 1 (MAGEA1) OTXAO193 MAGA1_HUMAN Decreases Methylation [89]
Melanoma-associated antigen 3 (MAGEA3) OTW3Y5M4 MAGA3_HUMAN Increases Expression [90]
Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) OTL1LBQJ KI2L1_HUMAN Increases Expression [91]
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) OTOVUTJD KI2L2_HUMAN Increases Expression [91]
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) OTFCN53B KI2L3_HUMAN Increases Expression [91]
Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1) OTPOSXFX KI3L1_HUMAN Increases Expression [91]
Killer cell immunoglobulin-like receptor 2DS4 (KIR2DS4) OT00N6UJ KI2S4_HUMAN Increases Expression [91]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [71]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Increases Expression [92]
Tuberin (TSC2) OT47LWI9 TSC2_HUMAN Increases Expression [93]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [71]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Increases Expression [75]
Homeobox protein Nkx-2.5 (NKX2-5) OTS1SAWM NKX25_HUMAN Increases Expression [94]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Affects Methylation [95]
Claudin-6 (CLDN6) OTEN8ID2 CLD6_HUMAN Increases Expression [69]
Claudin-8 (CLDN8) OT7IIWXG CLD8_HUMAN Increases Expression [69]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [75]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [96]
Cyclin-A1 (CCNA1) OTX4HD45 CCNA1_HUMAN Decreases Expression [97]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Decreases Activity [98]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [62]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Increases Expression [69]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Methylation [99]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [100]
N-myc-interactor (NMI) OTYVG3NM NMI_HUMAN Increases Expression [75]
NAD(P) transhydrogenase, mitochondrial (NNT) OTAIOGZK NNTM_HUMAN Increases Expression [68]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Affects Methylation [101]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [102]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [75]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Increases Expression [69]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Decreases Methylation [103]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Increases Expression [75]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [104]
Sodium/iodide cotransporter (SLC5A5) OTU7E9G7 SC5A5_HUMAN Increases Expression [105]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [75]
Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4) OTXN18OA KI2L4_HUMAN Increases Expression [91]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Increases Expression [75]
Calcium homeostasis modulator protein 2 (CALHM2) OTWWM6HI CAHM2_HUMAN Increases Expression [68]
Homeobox protein SIX2 (SIX2) OTYOVGSC SIX2_HUMAN Decreases Expression [68]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases Expression [106]
Sal-like protein 4 (SALL4) OTC08PR5 SALL4_HUMAN Affects Methylation [58]
Transcription factor MafB (MAFB) OTH2N3T8 MAFB_HUMAN Increases Expression [68]
Sodium/nucleoside cotransporter 1 (SLC28A1) OTXWVV9O S28A1_HUMAN Increases Response To Substance [107]
------------------------------------------------------------------------------------
⏷ Show the Full List of 275 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCI72KH DU-145 Investigative [1]
Adenocarcinoma DCVOEDM A549 Investigative [1]
Anaplastic large cell lymphoma DC1I4T3 SR Investigative [1]
Large cell lung carcinoma DCUJLM2 NCI-H460 Investigative [1]
Melanoma DCI0KUK MALME-3M Investigative [1]
Minimally invasive lung adenocarcinoma DCBRMR0 NCI-H322M Investigative [1]
Mixed endometrioid and clear cell carcinoma DC98NHM IGROV1 Investigative [1]
Plasma cell myeloma DC83XIY RPMI-8226 Investigative [1]
Pleural epithelioid mesothelioma DCAMQ24 NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Gefitinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
4 Azacitidine FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
6 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008 Mar;7(3):599-606.
7 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
8 EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011 May;34(4):372-81. doi: 10.1097/CJI.0b013e31821b724a.
9 Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol. 2019 Jun;93(6):1555-1571. doi: 10.1007/s00204-019-02453-2. Epub 2019 Apr 16.
10 DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011 Jul 15;117(14):3201-8. doi: 10.1002/cncr.25863. Epub 2011 Jan 24.
11 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
12 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
13 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
14 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
15 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
16 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
17 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
18 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
19 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
20 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
21 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
22 Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
23 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
24 EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
25 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
26 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
27 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
28 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
29 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
30 Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077.
31 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
32 Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
33 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
34 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
35 Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
36 The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
37 Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
38 Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016 Nov 1;310:140-149. doi: 10.1016/j.taap.2016.09.010. Epub 2016 Sep 14.
39 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
40 Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.
41 Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
42 Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
43 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
44 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
45 The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
46 Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29.
47 Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):359-73. doi: 10.1016/j.taap.2015.08.008. Epub 2015 Aug 20.
48 Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicol In Vitro. 2017 Oct;44:36-43.
49 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
50 The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3169-79. doi: 10.1158/1535-7163.MCT-07-0507.
51 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
52 BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.
53 E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. Chem Biol Interact. 2022 Feb 25;354:109798. doi: 10.1016/j.cbi.2022.109798. Epub 2022 Jan 6.
54 Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005 Oct 15;65(20):9176-84. doi: 10.1158/0008-5472.CAN-05-1556.
55 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
56 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
57 Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol. 2009 Mar;82(3):176-83. doi: 10.1111/j.1600-0609.2008.01189.x. Epub 2008 Dec 5.
58 Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer. 2007 Oct 1;121(7):1487-93. doi: 10.1002/ijc.22847.
59 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
60 A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
61 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
62 The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28.
63 Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett. 2003 Sep 30;144(2):247-56.
64 Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
65 Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol. 2008 Feb 15;75(4):965-72. doi: 10.1016/j.bcp.2007.10.018. Epub 2007 Oct 22.
66 Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 2015 May 8;8:46. doi: 10.1186/s13045-015-0143-3.
67 Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer. 2008 Jan 29;98(2):410-7. doi: 10.1038/sj.bjc.6604124. Epub 2008 Jan 22.
68 CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy. Arch Toxicol. 2023 Feb;97(2):441-456. doi: 10.1007/s00204-022-03404-0. Epub 2022 Nov 6.
69 Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9. Jpn J Ophthalmol. 2008 May-Jun;52(3):195-203. doi: 10.1007/s10384-008-0524-z. Epub 2008 Jul 27.
70 Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
71 Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 2009 Jan;328(1):107-15. doi: 10.1124/jpet.108.143560. Epub 2008 Sep 30.
72 Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
73 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
74 Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol Sin. 2008 Jan;29(1):105-12. doi: 10.1111/j.1745-7254.2008.00739.x.
75 Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81. doi: 10.1073/pnas.1011936108. Epub 2011 Jan 18.
76 Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.
77 Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
78 The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm. 2007 Jun;22(3):443-9. doi: 10.1089/cbr.2006.319.A.
79 Characterisation of human histone H1x. Biol Chem. 2005 Jun;386(6):541-51. doi: 10.1515/BC.2005.064.
80 Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med. 2010 Mar 28;3(2):95-102.
81 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
82 Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer. 2007 Jul 1;110(1):87-95. doi: 10.1002/cncr.22758.
83 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res. 2009 Jul 15;15(14):4572-80. doi: 10.1158/1078-0432.CCR-08-2518. Epub 2009 Jul 7.
84 DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
85 CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003 Aug;24(8):1337-45. doi: 10.1093/carcin/bgg086. Epub 2003 May 22.
86 Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3.
87 The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/?catenin pathway and DNA methyltransferase-1. Oncol Rep. 2017 Nov;38(5):3114-3120. doi: 10.3892/or.2017.5945. Epub 2017 Sep 7.
88 Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006 Nov;84(11):911-8. doi: 10.1007/s00109-006-0099-4. Epub 2006 Sep 22.
89 Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007 Sep;138(5):616-23. doi: 10.1111/j.1365-2141.2007.06707.x.
90 Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20.
91 DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2009 Feb;130(2):213-24. doi: 10.1016/j.clim.2008.08.009. Epub 2008 Oct 22.
92 Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells. Biomed Pharmacother. 2010 Jan;64(1):54-7. doi: 10.1016/j.biopha.2009.04.041. Epub 2009 Sep 2.
93 Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009 Jul;33(7):891-7. doi: 10.1016/j.leukres.2009.01.041. Epub 2009 Feb 27.
94 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 2008 Aug;95(2):137-48. doi: 10.1111/j.1423-0410.2008.01076.x. Epub 2008 Jun 28.
95 Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 2007 Jun;60(6):664-9. doi: 10.1136/jcp.2006.038331.
96 Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009 Feb 1;182(3):1500-8. doi: 10.4049/jimmunol.182.3.1500.
97 Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007 Nov 15;110(10):3648-55. doi: 10.1182/blood-2007-06-096701. Epub 2007 Aug 13.
98 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
99 Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res. 2004 Oct 15;10(20):7100-7. doi: 10.1158/1078-0432.CCR-04-0337.
100 Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine. Eur J Cancer. 2014 Dec;50(18):3243-61. doi: 10.1016/j.ejca.2014.09.012. Epub 2014 Oct 13.
101 Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007 Dec;25(8):685-90. doi: 10.1080/07357900701561131.
102 [5-azacytidine enhances anti-tumor efficacy of doxorubicin to neuroblastoma cell lines]. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Dec;9(6):577-9.
103 Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017 Mar;91(3):189-196. doi: 10.1124/mol.116.106757. Epub 2016 Dec 21.
104 p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
105 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):797-826. doi: 10.1677/erc.1.01143.
106 Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6. doi: 10.1073/pnas.0907109106. Epub 2009 Sep 10.
107 Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009 Jan;8(1):225-31. doi: 10.1158/1535-7163.MCT-08-0743.